MTIF2 impairs 5 fluorouracil-mediated immunogenic cell death in hepatocellular carcinoma in vivo: Molecular mechanisms and therapeutic significance-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

MTIF2 impairs 5 fluorouracil-mediated immunogenic cell death in hepatocellular carcinoma in vivo: Molecular mechanisms and therapeutic significance

Published:2021-01 Issue: Volume:163 Page:105265
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Xu Dafeng,Wang Yu,Wu Jincai,Zhang Zhensheng,Chen Jiacheng,Xie Mingwei,Tang Rong,Cheng Chen,Chen Liang,Lin Shiyun,Luo Xiangxiang,Zheng Jinfang

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Pharmacology

Reference36 articles.

1. The diagnosis and treatment of hepatocellular carcinoma;Hartke;Semin. Diagn. Pathol.,2017

2. Hepatocellular carcinoma in the era of immunotherapy;Sim;Curr. Probl. Cancer,2018

3. Hepatocellular carcinoma: review of epidemiology, screening, imaging diagnosis, response assessment, and treatment;Clark;Curr. Probl. Diagn. Radiol.,2015

4. The evolving epidemiology of hepatocellular carcinoma: a global perspective;Wallace;Expert Rev. Gastroenterol. Hepatol.,2015

5. The immunosuppressive tumor microenvironment in hepatocellular carcinoma;Pang;Cancer Immunol. Immunother.,2009

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plant-derived natural compounds: A new frontier in inducing immunogenic cell death for cancer treatment;Biomedicine & Pharmacotherapy;2024-08

2. Single-cell analysis revealed that MTIF2 could promote hepatocellular carcinoma progression through modulating the ROS pathway;Heliyon;2024-07

3. HMGB1 Signaling-Mediated Tumor Immunity in Cancer Progress;Frontiers in Bioscience-Landmark;2023-10-24

4. Overexpression of MRPL19 in predicting poor prognosis and promoting the development of lung adenocarcinoma;Translational Lung Cancer Research;2023-07

5. Research progress in inducing immunogenic cell death of tumor cells;Frontiers in Immunology;2022-11-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3